Get the Stockscreener App
0.3229
2.18%
-0.0072
After Hours:
.33
0.0071
+2.20%
Bioxcel Therapeutics Inc Stock (BTAI) Latest News
BioXcel Therapeutics stock hits 52-week low at $0.3 - Investing.com
Are Investors Keen On Selling Holdings In BioXcel Therapeutics Inc (NASDAQ: BTAI)? - Stocks Register
Why BioXcel Therapeutics Shares Are Rising Tuesday - MSN
BioXcel Therapeutics expands board, appoints new director - MSN
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Sees Large Drop in Short Interest - Defense World
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Shares Sold by Jane Street Group LLC - Defense World
Bioxcel Therapeutics Appoints Dr. Rajiv Patni to Board - TipRanks
Thinking about buying stock in Hanryu Holdings, Absci Corp, Spero Therapeutics, BioXcel Therapeutics, or Cybin? - Marketscreener.com
BioXcel Therapeutics files to sell 5.1M shares of common stock by selling shareholders - MSN
BioXcel Therapeutics Amends Employment Agreements for Executives - Defense World
BioXcel Therapeutics (NASDAQ:BTAI) Earns “Underperform” Rating from Bank of America - Defense World
BioXcel Therapeutics amends executive compensation - Investing.com
BioXcel Therapeutics amends executive compensation By Investing.com - Investing.com UK
Top execs at New Haven-based BioXcel face compensation reductions amid company’s financial struggles - Hartford Business Journal
Bioxcel Therapeutics Revises Executive Compensation Structure - TipRanks
BioXcel Therapeutics (NASDAQ:BTAI) Price Target Lowered to $5.00 at Canaccord Genuity Group - Defense World
Canaccord cuts BioXcel Therapeutics shares target, keeps Buy rating - Investing.com
State Street Corp Sells 47,600 Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) - Defense World
Axsome to seek approval for Alzheimer's-related agitation drug despite mixed data - Reuters
BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade - MSN
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Shares Sold by BNP Paribas Financial Markets - Defense World
Bioxcel therapeutics CEO sells shares worth $1,131 By Investing.com - Investing.com South Africa
Bioxcel therapeutics CFO Richard Steinhart sells $206 in stock By Investing.com - Investing.com Nigeria
Bioxcel therapeutics executive sells $153 in stock By Investing.com - Investing.com Australia
Bioxcel therapeutics' chief scientific officer sells $151 worth of stock By Investing.com - Investing.com Canada
Bioxcel therapeutics CFO Richard Steinhart sells $206 in stock - Investing.com India
Bioxcel therapeutics executive sells $153 in stock - Investing.com
Bioxcel therapeutics CEO sells shares worth $1,131 - Investing.com
Bioxcel therapeutics exec sells $58 in stock By Investing.com - Investing.com UK
BioXcel Therapeutics stock hits 52-week low at $0.35 - Investing.com India
BioXcel Therapeutics stock hits 52-week low at $0.35 By Investing.com - Investing.com Nigeria
BioXcel Therapeutics (STU:BX2) 5-Day RSI : 7.74 (As of Dec. 05, 2024) - GuruFocus.com
BioXcel Therapeutics stock hits 52-week low at $0.4 By Investing.com - Investing.com Canada
BioXcel Therapeutics stock hits 52-week low at $0.4 - Investing.com India
BioXcel Therapeutics announces pricing of $7M public offering - MSN
BioXcel Therapeutics stock hits 52-week low at $0.5 By Investing.com - Investing.com Australia
BioXcel Therapeutics Prices of $7 Million Public Offering - citybiz
BioXcel Therapeutics stock hits 52-week low at $0.5 - Investing.com India
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):